NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $18.00 -0.08 (-0.44%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$18.00 0.00 (0.00%) As of 11/17/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Denali Therapeutics Stock (NASDAQ:DNLI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Denali Therapeutics alerts:Sign Up Key Stats Today's Range$17.17▼$18.2650-Day Range$17.61▼$21.6052-Week Range$15.34▼$27.30Volume1.13 million shsAverage Volume1.53 million shsMarket Capitalization$2.89 billionP/E RatioN/ADividend YieldN/APrice Target$35.71Consensus RatingModerate Buy Company Overview Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California. Its research and development programs target conditions including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier. Denali was co-founded by Ryan Watts, who serves as the company’s chief executive officer. Its medicines remain in development, and the company’s work includes research and clinical testing of potential treatments for patients with neurological conditions.AI Generated. May Contain Errors. Read More Denali Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreDNLI MarketRank™: 3.686700426435 of 5 starsDenali Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 149th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDenali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 13 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialDenali Therapeutics has a consensus price target of $35.71, representing about 98.4% upside from its current price of $18.00.Amount of Analyst CoverageDenali Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Denali Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Denali Therapeutics are expected to grow in the coming year, from ($2.62) to ($2.36) per share.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.15% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 9.91.Change versus previous monthShort interest in Denali Therapeutics has recently decreased by 5.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.53 News SentimentDenali Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Denali Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows6 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,882.00 in company stock.Percentage Held by Insiders9.70% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNLI Stock News HeadlinesTranscript : Denali Therapeutics Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 02:40 PMNovember 17 at 2:56 PM | marketscreener.comMDenali Therapeutics Inc. (NASDAQ:DNLI) Stock Has Consensus Target Price of $35.71November 16 at 2:28 AM | americanbankingnews.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected. | Porter & Company (Ad)Denali Therapeutics (NASDAQ:DNLI) Research Coverage Started at Wells Fargo & CompanyNovember 16 at 1:36 AM | americanbankingnews.comTranscript : Denali Therapeutics Inc. Presents at Stifel 2026 Healthcare Conference 2026, Nov-11-2026 09:20 AMNovember 14, 2026 | marketscreener.comMDenali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptNovember 13, 2026 | seekingalpha.comDenali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)November 13, 2026 | seekingalpha.comGuggenheim reaffirms top pick in Biotech after Q3 resultsNovember 9, 2026 | uk.finance.yahoo.comSee More Headlines DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $16.51 at the beginning of the year. Since then, DNLI stock has increased by 9.0% and is now trading at $18.00. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) posted its earnings results on Tuesday, November, 3rd. The company reported $0.37 EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.64. The firm earned $17.78 million during the quarter, compared to the consensus estimate of $12.67 million. Read the conference call transcript. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $250 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 13,888,888 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' top institutional investors include State Street Corp (4.17%), Goldman Sachs Group Inc. (2.34%), Fisher Asset Management LLC (1.54%) and Pictet Asset Management Holding SA (0.99%). Insiders that own company stock include Ryan J Watts, Alexander O Schuth, Carole Ho, Vicki L Sato and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Intel (INTC), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Tesla (TSLA) and Boston Scientific (BSX). Company Calendar Last Earnings11/03/2026Today11/17/2026UBS Global Biopharma Conference 202611/17/2026Jefferies Global Healthcare Conference11/18/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 6 days, DNLI's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DNLI CIK1714899 Webwww.denalitherapeutics.com Phone(650) 866-8547FaxN/AEmployees507Year Founded2015Price Target and Rating Average Price Target for Denali Therapeutics$35.71 High Price Target$42.00 Low Price Target$24.00 Potential Upside/Downside+98.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$512.54 million Net MarginsN/A Pretax Margin-1,470.03% Return on Equity-54.94% Return on Assets-42.15% Debt Debt-to-Equity Ratio0.01 Current Ratio6.21 Quick Ratio5.94 Sales & Book Value Annual Sales$330.53 million Price / Sales8.73 Cash FlowN/A Price / Cash FlowN/A Book Value$5.78 per share Price / Book3.11Miscellaneous Outstanding Shares160,290,000Free Float144,743,000Market Cap$2.89 billion OptionableOptionable Beta1.08 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:DNLI) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.